Syndax Pharmaceuticals (SNDX) financial statements
Syndax Pharmaceuticals reported revenue of $172M in fiscal 2025, up 73.3% a year over 9 years.
Net income was -$285M and the operating margin -158.4%, against -3587.4% in 2016.
Free cash flow was -$323M.
The diluted share count rose 493% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Syndax Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $2M | $2M | $2M | $2M | $140M | $0 | $0 | $24M | $172M |
| Research and development | $32M | $48M | $60M | $43M | $50M | $88M | $118M | $163M | $242M | $259M |
| Selling, general and admin | $13M | $16M | $17M | $16M | $23M | $25M | $33M | $67M | $121M | $180M |
| Operating income | -$44M | -$62M | -$76M | -$58M | -$71M | $26M | -$152M | -$230M | -$340M | -$273M |
| Interest expense | — | — | — | — | $2M | $2M | $3M | $208,000 | -$1,000 | $6,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | $433,000 |
| Net income | -$44M | -$61M | -$74M | -$56M | -$73M | $25M | -$149M | -$209M | -$319M | -$285M |
| EPS (diluted) | -$3.22 | -$2.90 | -$2.92 | -$1.84 | -$1.87 | $0.46 | -$2.46 | -$2.98 | -$3.72 | -$3.29 |
| Diluted shares | 15M | 21M | 25M | 30M | 41M | 54M | 61M | 70M | 86M | 87M |
| Operating margin | -3587.4% | -2939.0% | -5001.7% | -3792.9% | -4708.2% | 18.8% | — | — | -1434.4% | -158.4% |
| Net margin | -3645.2% | -2884.3% | -4875.5% | -3694.6% | -4822.5% | 17.8% | — | — | -1346.1% | -165.6% |
Balance sheet
Fiscal years, from Syndax Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $105M | $130M | $81M | $60M | $293M | $440M | $476M | $571M | $573M | $394M |
| Receivables | — | — | — | — | — | — | — | $0 | $8M | $38M |
| Inventory | — | — | — | — | — | — | — | $0 | $366,000 | $33M |
| Total current assets | $109M | $133M | $83M | $62M | $299M | $448M | $490M | $581M | $603M | $528M |
| Property, plant and equipment | $260,000 | $267,000 | $373,000 | $281,000 | $192,000 | $278,000 | $20,000 | $8,000 | $0 | $181,000 |
| Total assets | $109M | $137M | $84M | $64M | $301M | $450M | $497M | $613M | $725M | $530M |
| Total current liabilities | $10M | $16M | $16M | $18M | $19M | $21M | $29M | $58M | $104M | $120M |
| Total liabilities | $25M | $33M | $31M | $32M | $48M | $41M | $30M | $59M | $437M | $465M |
| Shareholders' equity | $84M | $104M | $53M | $32M | $252M | $408M | $467M | $554M | $288M | $65M |
| Net debt | -$24M | -$35M | -$34M | -$25M | -$115M | -$222M | -$74M | -$295M | $184M | $215M |
Cash flow
Fiscal years, from Syndax Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$35M | -$47M | -$69M | -$51M | -$71M | $29M | -$134M | -$161M | -$275M | -$323M |
| Capital spending | $261,000 | $84,000 | $187,000 | — | $0 | $129,000 | $0 | $0 | $0 | $187,000 |
| Free cash flow | -$35M | -$47M | -$69M | — | -$71M | $29M | -$134M | -$161M | -$275M | -$323M |
| Stock-based compensation | $5M | $5M | $6M | $6M | $9M | $13M | $16M | $31M | $43M | $48M |
| Free cash flow margin | -2903.1% | -2251.2% | -4529.9% | — | -4697.4% | 20.8% | — | — | -1160.9% | -187.5% |
Questions
What was Syndax Pharmaceuticals's revenue in 2025?
$172M in fiscal 2025, from its 10-K filing.
How much free cash flow does Syndax Pharmaceuticals generate?
-$323M in fiscal 2025 (operating cash flow minus capital spending).
From Syndax Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.